Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection
CGMP Deviations
Par Health announced this recall on Sep 18, 2026. FDA has not yet published its classification (Class I, II or III) for it; that usually follows within a few weeks, and this page will then point to the classified recall.
Presence of particulate matter identified as cellulose or stopper material
Cause type: Particulate / foreign matter
Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables.
Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) for Intravenous Infusion
Compare with the code on your package — the lot numbers are listed in FDA’s notice.
Drug: Dexmedetomidine
From the FDA NDC directory, for the product code in this announcement.
| Product | Strength | Form & route | Labeler |
|---|---|---|---|
| Dexmedetomidine Hydrochloride NDC 42023-0187 |
4 ug/mL | Injection, Solution Intravenous |
Par Health USA, LLC |
Check your lot number. Firm-announced recalls are usually the serious ones. Find the lot number on your package and compare it with the lots listed in FDA’s notice; if it matches, do not use it and speak to your pharmacist or prescriber today. Do not stop a prescribed medication without advice.
CGMP Deviations
Lack of Assurance of Sterility: Leaking/damaged syringes.
cGMP deviations: Temperature abuse
Cross Contamination with other products: trace amounts of lidocaine
Cross Contamination with other products: trace amounts of lidocaine
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.